|
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.3 EUR | +4.29% |
|
+10.94% | +71.36% |
| 07-03 | Nyxoah Secures $40 Million Loan Facility from European Investment Bank | MT |
| 07-01 | Nyxoah Submits Final Module of Premarket Approval Application for Sleep Apnea Therapy to FDA | MT |
Nyxoah S.A. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported sales was EUR 1.22 million compared to EUR 0.441 million a year ago. Net loss was EUR 11.91 million compared to EUR 11.91 million a year ago.
Basic loss per share from continuing operations was EUR 0.415 compared to EUR 0.46 a year ago. Diluted loss per share from continuing operations was EUR 0.415 compared to EUR 0.46 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| +71.36% | 260M | |
| +0.91% | 204B | |
| +3.74% | 178B | |
| +28.89% | 154B | |
| +31.66% | 112B | |
| +0.95% | 64.16B | |
| +19.45% | 54.88B | |
| -3.44% | 46.69B | |
| -9.28% | 36.8B | |
| -0.10% | 35.26B |
NYXOAH SA 
